48 Biggest Movers From Friday

Gainers

• Corvus Pharmaceuticals, Inc. CRVS shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
• Helbiz, Inc. HLBZ shares surged 96.6% to close at $17.69 on Friday after the company announced its media unit has entered into an agreement with FOX Networks to broadcast the Italian Serie B championship across the USA and the Caribbean.
• Priority Technology Holdings, Inc. PRTH rose 47.2% to settle at $7.45. Priority Technology disclosed that it has completed the acquisition of Finxera Holdings, Inc.
• Innate Pharma S.A. IPHA shares gained 40.9% to close at $8.10 as its partner AstraZeneca Plc AZN presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021. SVB Leerink maintained Innate Pharma with an Outperform and raised the price target from $7 to $9.
• ForgeRock, Inc. FORG jumped 29.2% to close at $47.15. The company recently priced its IPO at $25 per share.
• X Financial XYF surged 21.5% to settle at $4.80.
• Spire Global, Inc. SPIR rose 202.% to close at $13.71. Spire Global recently announced plans to acquire exactEarth for $161.2 million.
• Surface Oncology, Inc. SURF gained 18.1% to close at $7.10.
• Actinium Pharmaceuticals, Inc. ATNM rose 17.2% to close at $7.83. The company recently announced it completed enrollment in the pivotal Phase 3 SIERRA trial of iomab-B.
• OraSure Technologies, Inc. OSUR gained 16.7% to close at 13.38. Raymond James said the company won a $512 million contract.
• Akoya Biosciences, Inc. AKYA surged 16% to settle at $21.00.
• S&W Seed Company SANW gained 15.2% to close at $2.95.
• Berkeley Lights, Inc. BLI rose 15.2% to settle at $27.11.
• Capital Senior Living Corporation CSU climbed 15% to close at $33.53.
• Evelo Biosciences, Inc. EVLO surged 14.1% to close at $8.34. Evelo Biosciences recently announced issuance of U.S. Patent for pharmaceutical compositions of single strains of naturally occurring bacteria as medicines.
• CuriosityStream Inc. CURI gained 13.6% to close at $12.57. JP Morgan initiated coverage on CuriosityStream with an Overweight rating and announced a price target of $15.
• Heritage Insurance Holdings, Inc. HRTG jumped 12.8% to close at $6.25.
• SmileDirectClub, Inc. SDC gained 11.7% to close at $6.70 as traders on social media circulated the stock, highlighting high short interest.
• I-Mab IMAB shares climbed 11.3% to settle at $75.85.
• Doma Holdings Inc. DOMA climbed 10.2% to close at $8.64. Oppenheimer initiated coverage on Doma Holdings with an Outperform rating and announced a price target of $11.
• Lucid Group, Inc. LCID gained 8.5% to settle at $22.96. Lucid Group gained over 6% on Thursday after the company's Lucid Air Dream Edition Range received an official EPA rating of 520 miles of range.
• Berkshire Grey, Inc. BGRY rose 6.7% to close at $7.15.
• Thermo Fisher Scientific Inc. TMO gained 6.5% to close at $596.80 after the company issued FY22 EPS and sales guidance above analyst estimates.
• Invesco Ltd. IVZ rose 5.5% to close at $26.25. Invesco is in merger talks with State Street's asset management business, according to the Wall Street Journal.
• BeiGene, Ltd. BGNE rose 4.7% to close at $403.14. BeiGene CEO John Oyler reported the sale of 411,838 shares in a Form 4 filing on Thursday.

Check out these big penny stock gainers and losers

Losers

• Protagonist Therapeutics, Inc. PTGX shares tumbled 62% to close at $17.53 on Friday after the company reported the FDA placed a clinical hold on rusfertide development program.
• TCR2 Therapeutics Inc. TCRR dropped 36.5% to close at $9.99 after the company announced interim results from an ongoing Phase 1/2 trial of gavo-cel for the treatment of refractory mesothelin-expressing solid tumors.
• Offerpad Solutions Inc OPAD shares declined 31.8% to settle at $13.63. Offerpad Solutions shares jumped over 58% on Thursday amid increased retail investor interest in the stock on social media.
• IronNet Cybersecurity, Inc. IRNT declined 26.9% to settle at $30.26. IronNet shares climbed over 28% on Thursday amid increased retail investor interest in the stock on social media.
• Eliem Therapeutics, Inc. ELYM fell 21.9% to close at $18.77. Eliem Therapeutics recently reported a Q2 loss of $3.11 per share.
• Janux Therapeutics, Inc. JANX declined 20.3% to close at $27.39.
• Elite Education Group International Limited EEIQ dipped 19.1% to settle at $6.31.
• Sentage Holdings Inc. SNTG fell 18% to close at $2.50.
• ZIVO Bioscience, Inc. ZIVO declined 16.7% to settle at $2.80.
• TMC the metals company Inc. TMC fell 16.2% to close at $10.38.
• Icosavax, Inc. ICVX declined 16.2% to settle at $33.06. Icosavax recently reported a Q2 loss of $2.86 per share.
• Century Therapeutics, Inc. IPSC fell 15.4% to close at $24.76.
• SigmaTron International, Inc. SGMA declined 15.2% to settle at $9.99.
• Gritstone bio, Inc. GRTS fell 15.1% to close at $11.50. Gritstone bio announced results with its SLATE v1 product ("off-the-shelf" shared neoantigen immunotherapy).
• Auddia Inc. AUUD dipped 14.3% to settle at $2.69 after Maxim Group initiated coverage on the stock with a Buy rating and announced a $9 price target.
• Verve Therapeutics, Inc. VERV fell 14.3% to close at $59.88.
• Snap One Holdings Corp. SNPO dropped 13.4% to settle at $17.25.
• Tenaya Therapeutics, Inc. TNYA declined 13.3% to close at $20.85. Tenaya Therapeutics, earlier during the month, reported a Q2 loss of $13.26 per share.
• EZFill Holdings Inc. EZFL shares fell 12.3% to close at $4.56 after jumping around 15% on Thursday. The company recently priced its IPO at 4 per share.
• AEye, Inc. LIDR fell 11.5% to close at $8.70.
• Generation Bio Co. GBIO fell 7.5% to close at $25.13.
• Vera Therapeutics, Inc. VERA fell 6.9% to close at $20.93 after tumbling 26% on Thursday.
• Syros Pharmaceuticals, Inc. SYRS fell 6.8% to close at $5.08. Syros recently said that the first patient was dosed in SELECT-AML-1 trial of tamibarotene in combination with venetoclax and azacitidine in newly diagnosed unfit AML.